Rituximab Approved Indications
Rituximab is FDA-approved for multiple CD20-positive B-cell malignancies, chronic lymphocytic leukemia, rheumatoid arthritis, ANCA-associated vasculitis (granulomatosis with polyangiitis and microscopic polyangiitis), and moderate-to-severe pemphigus vulgaris. 1
Oncologic Indications
Non-Hodgkin's Lymphoma (NHL)
Rituximab is approved for adult patients with CD20-positive B-cell NHL in the following settings 1:
- Relapsed or refractory, low-grade or follicular NHL as monotherapy
- Previously untreated follicular NHL in combination with first-line chemotherapy, with maintenance therapy option for responders
- Non-progressing low-grade NHL as monotherapy after first-line CVP chemotherapy
- Previously untreated diffuse large B-cell NHL in combination with CHOP or other anthracycline-based regimens
Pediatric Mature B-Cell Malignancies
For pediatric patients aged 6 months and older 1:
- Previously untreated, advanced-stage CD20-positive DLBCL, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia in combination with chemotherapy
Chronic Lymphocytic Leukemia (CLL)
Approved for previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide 1.
Burkitt Lymphoma/Leukemia
The addition of rituximab to intensive chemotherapy is now standard of care for adult Burkitt lymphoma/leukemia, improving long-term event-free survival by approximately 20% (from 60-70% to 80-89%) 2.
Autoimmune and Inflammatory Indications
Rheumatoid Arthritis
Approved in combination with methotrexate for moderately-to-severely active RA in patients with inadequate response to one or more TNF antagonist therapies 1. The dosing is two 1,000 mg IV infusions separated by 2 weeks, repeated every 24 weeks or based on clinical evaluation (but not sooner than every 16 weeks) 1.
ANCA-Associated Vasculitis
Approved for granulomatosis with polyangiitis (Wegener's granulomatosis) and microscopic polyangiitis in adult and pediatric patients aged 2 years and older, in combination with glucocorticoids 1. This approval was based on the RAVE trial demonstrating efficacy in induction and maintenance of remission 3.
Pemphigus Vulgaris
Approved for moderate-to-severe pemphigus vulgaris in adult patients 1. While regulatory approval varies by country, rituximab is increasingly recognized as first-line therapy in combination with corticosteroids, using the rheumatoid arthritis protocol (2 × 1 g infusions, 2 weeks apart) 4.
Off-Label Uses with Strong Evidence
Waldenström's Macroglobulinemia
Rituximab is widely used as monotherapy or in combination regimens, with overall response rates of 30-60% for standard dosing and 35-45% for extended schedules 5. Critical caveat: Patients with baseline IgM levels ≥4000 mg/dL should undergo prophylactic plasmapheresis or avoid rituximab initially due to risk of IgM flare causing hyperviscosity 5.
Post-Transplant Lymphoproliferative Disorder (PTLD)
Rituximab monotherapy (375 mg/m² weekly for up to 4 doses) is first-line therapy for EBV-PTLD after hematopoietic stem cell transplantation, with positive outcomes in approximately 70% of patients 6. It should be combined with reduction of immunosuppression when possible 6.
Mantle Cell Lymphoma
Rituximab-containing regimens are standard for advanced MCL, though no single regimen is established as superior 7. For patients achieving complete response to R-CHOP who are not candidates for high-dose therapy/autologous stem cell transplant, maintenance rituximab every 8 weeks until progression is recommended (category 1) 7.
Important Safety Considerations
Fatal infusion-related reactions occur in approximately 80% of cases during the first infusion 1. Rituximab should only be administered by healthcare professionals with appropriate medical support to manage severe reactions 1.
Boxed warnings include 1:
- Fatal infusion-related reactions
- Severe mucocutaneous reactions with fatal outcomes
- Hepatitis B virus reactivation leading to fulminant hepatitis and death
- Progressive multifocal leukoencephalopathy resulting in death
Late-onset neutropenia and hypogammaglobulinemia can occur, particularly when combined with chemotherapy 5, 8. Long-term B-cell depletion may impair vaccine responses 8.